Pioneering genomic analysis

At Congenica we’re in the business of changing lives for the better.

We are a digital health company enabling genomic medicine with the world leading Clinical Decision Support platform for clinical use for the rapid analysis and interpretation of genomic data.

Built on a foundation of clinical expertise, we are driven to empower healthcare professionals worldwide to transform health and wellness, improving lives by converting genomic data into actionable information.

Leveraging proprietary artificial intelligence (AI) and automation, our CE-IVD platform can analyze the entire human genome, to not only find the problem but go further, collect a wealth of information, trillions of data points, then interpret and understand every detail.

Learn more about our platform

Ending diagnostic odysseys

People with genetic diseases wait an average of five years for a diagnosis. Congenica is working towards a future where diagnostic odysseys are shortened from years to days, helping to provide appropriate genomic information for more people, faster

Generating value

Congenica improves the opportunity for genomic characterization of disease. Supporting laboratories to achieve 30% higher analytical yields than averages and reduce analysis times and costs by 95%

Improving people’s lives

We support the global genomic community to achieve the best outcomes possible. Our genomic analysis solutions aid the disease characterization and research supporting people to maintain wellness and lead fuller lives

Partnerships

Our software is trusted by world-leading centers of excellence, diagnostic laboratories, healthcare organizations and biopharmaceutical companies.
Congenica is proud to have been selected by Genomics England as the exclusive Clinical Decision Support Platform for clinical use for the UK NHS Genomic Medicine Service – a groundbreaking national initiative and a world first.

Using Congenica we significantly increased our analytical yield and lab efficiency.

Gianpiero Cavalleri Ph.D.
Professor of Human Genetics at Royal College of Surgeons Ireland (RCSI), Deputy Director of the SFI FutureNeuro Research Centre and Director of the Human Genetic Variation Research Group

Thought Leadership

Congenica is helping to drive the conversation in genomics. Discover more about the impact of our work in our peer-reviewed publications and resource library.

Our Team

Our team includes bioinformaticians, clinical experts, software engineers and A.I. innovators.
We seek talented people who are driven to make a difference and who want to collaborate with like-minded individuals to revolutionize healthcare. If you think you’ve got what it takes and want to take your career to the next level, visit our careers page.

Members of the Board

Andy Richards, CBE, PhD

Position: Chairman
Categories: board

Andy is a well-established entrepreneur and builder of biotechnology, healthcare and diagnostic ventures. He brings a strong business focus and an in-depth knowledge of the industry and company scale up. He is currently Chairman of Arecor, Abcodia and Closed Loop Medicine and is a director of Owlstone Medical and Ieso Digital Health. He is Chairman of BBT the Babraham Research Campus and a director of Cancer Research Technology Ltd (the commercial board of Cancer Research UK). Andy is a graduate of Cambridge University with a PhD in Chemistry and a track record as a founder, active investor in and director of more than 25 innovative healthcare and life-science companies, including Vectura plc and Arakis.

Andy Richards, CBE, PhD

Chairman

Matthew Hurles, PHD

Position: Scientific Director
Categories: board, SAB

Matt is Head of Human Genetics and Senior Group Leader at the Wellcome Trust Sanger Institute. Matt is the scientific director of the Deciphering Developmental Disorders program and was a major contributor to the UK 10K projects. He has pioneered the analysis of whole exomes in clinically relevant disorders that previously failed diagnostic methods and has led an initiative to characterize structural variation in the human genome. Matt has been awarded the Balfour Lecture by the Genetics Society and the Crick Lecture prize for accomplishments in genetics and is a Fellow of the Royal Society.

Matthew Hurles, PHD

Scientific Director

Michael Anstey, PhD

Position: Non-Executive Director
Categories: board

Michael is an Investment Director at Cambridge Innovation Capital plc and is focused on Healthcare businesses. Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group’s (BCG) Toronto office. Michael has experience in advising multinational healthcare businesses across North America, Europe, India, and Japan on a broad range of topics, including corporate strategy, sales and marketing, new launches, R&D and medical strategy, and M&A.

Michael Anstey, PhD

Non-Executive Director

David Shi

Position: Non-Executive Director
Categories: board

David is the president and CEO of Digital China Health Technologies Corporation Limited. In China, he is the organizer of a national cancer database which includes information platforms in the National Cancer Center and provincial cancer hospitals, and built the National Population Macro Management Decision Model, approved by the UN. David serves as the Deputy Secretary General of the National Union for big data industry, the vice chairman of the national population medical big data Specialized Committee, and the Deputy Secretary-General of the Cancer Professional Committee on Healthcare Big Data.

David Shi

Non-Executive Director

Alastair Kilgour

Position: Non-Executive Director
Categories: board

Alastair has over 30 years’ experience founding and leading various businesses and teams in broking, banking and fund management. Alastair was a Global Partner in Lazard Frere LLP. Currently he is a founder and CIO of Parkwalk Advisors, one of the biggest investors in UK University Technology Spinouts with a portfolio of over 80 companies.

Alastair Kilgour

Non-Executive Director

Heiner Dreismann, PhD

Position: Non-Executive Director
Categories: board

Heiner is a seasoned executive with more than 35 years of experience in the life sciences and health care industries. He was previously the President and CEO of Roche Molecular Systems, the world leader in molecular diagnostics, where he made significant contributions to the organisational and financial growth of the company’s molecular business area. Since leaving Roche Heiner has served on the board of a number of private and public biotechnology and healthcare companies in the United States, Europe and Israel.

Heiner Dreismann, PhD

Non-Executive Director

Robert Denison

Position: Chief Executive Officer
Categories: board, management

Rob has over 20 years experience in technology R&D and high growth software businesses. After founding and selling his own disruptive technology company he has been part of the executive team of businesses in R&D consultancy, biomedical development, and high volume webs services delivery. His experience ranges from aggressive start ups through to high growth multi billion dollar market cap organisations, where he has lead a broad range of areas of the business in CTO/CIO or COO positions. During his career he has been a member of the core team of large open source projects and has extensive experience of managing key technology partnerships.

Robert Denison

Chief Executive Officer
Shannon Lee

Shannon Lee, FIA

Position: Non-Executive Director
Categories: board

Shannon is a Commercial Director at Legal & General working in the Fintech & Direct Investment team. Her role is to work closely with the team’s portfolio of start-up and scale-up businesses driving performance,  as well as scanning the market for new opportunities. She has worked in a wide variety of roles sponsoring large financial, regulatory and people projects across insurance, as well as transformational programmes. She has experience across technical and functional roles, and newer fields such as Fintech and Climate Change, and she has worked internationally. Shannon joined Legal & General from PricewaterhouseCoopers where she was a Senior Consultant and she has prior experience working for consultancies in New York City and Toronto. She is a Fellow of the Institute and Faculty of Actuaries.

Shannon Lee

Shannon Lee, FIA

Non-Executive Director

Senior Management Team

Richard Durbin, PhD

Position: Informatics Director
Categories: management, SAB

Richard is a Professor in the Department of Genetics at Cambridge University and Associate Faculty of the Wellcome Sanger Institute. A pioneer in genome sequencing and bioinformatics for over 25 years, he has developed sequence data analysis tools that are now standards in the field, including the alignment software bwa and the SAM/BAM format which underpin most clinical genomic data analysis. Richard has also made significant contributions to the Ensembl resource for vertebrate genome annotation, and the TreeFam and Pfam databases and led the international 1000 Genomes Project and the UK 10K Genome Project. Richard is a Fellow of the Royal Society and a Member of EMBO.

Richard Durbin, PhD

Informatics Director

Philip Beales, PhD

Position: Chief Medical Officer
Categories: management, SAB

Phil is a consultant clinical geneticist and Professor of Medical and Molecular Genetics at the UCL Institute of Child Health (ICH), an NIHR Senior Investigator, Honorary Consultant in Clinical Genetics at Great Ormond Street Hospital (GOSH) and the lead on Personalized Medicine for UCL. He is an internationally recognized expert in the genetics and pathogenesis of ciliopathies and pioneering use of next generation sequencing in mapping disease genes in this area.

Philip Beales, PhD

Chief Medical Officer

Alistair Johnson

Position: Chief Professional Services Officer
Categories: management

Alistair has over 20 years’ experience in project consultancy, product management and marketing in a range of industries including Finance, IT Security, Medicines Supply Chain Management and IT Service Management. He has worked in companies of all sizes ranging from start-ups to global enterprises including Symantec and Infor. Alistair is uniquely positioned to understand and address the technical and commercial challenges of delivering a secure, high quality system with user experience at its core.

Alistair Johnson

Chief Professional Services Officer

Robert Denison

Position: Chief Executive Officer
Categories: board, management

Rob has over 20 years experience in technology R&D and high growth software businesses. After founding and selling his own disruptive technology company he has been part of the executive team of businesses in R&D consultancy, biomedical development, and high volume webs services delivery. His experience ranges from aggressive start ups through to high growth multi billion dollar market cap organisations, where he has lead a broad range of areas of the business in CTO/CIO or COO positions. During his career he has been a member of the core team of large open source projects and has extensive experience of managing key technology partnerships.

Robert Denison

Chief Executive Officer

Jonathan Day

Position: Senior Director - Quality and Regulatory Affairs
Categories: management

Jonathan has over 20 years’ experience in the Life Sciences with a focus on Medical Devices including In Vitro Diagnostics and Software as a Medical Device. He has worked in both the United States and the United Kingdom starting in basic research moving to molecular biology manufacturing and on to senior global compliance and regulatory roles for large multinational organisations in addition to start-ups and SMEs. Jonathan’s experience includes process excellence, regulatory strategy, remediation activities, new product introduction and submissions, in addition to building departments and compliance programmes. Jonathan holds a BSc(hons) degree in Microbiology from King’s College London.

Jonathan Day

Senior Director - Quality and Regulatory Affairs

Jayesh Pankhania

Position: Chief Financial Officer
Categories: management

Jayesh is a Chartered Accountant with nearly 30 years’ senior finance experience. Between 2018 and 2021 he was Chief Financial Officer of Horizon Discovery plc, a life science tools company, where he led the development of its strategy and prepared it for a Nasdaq listing. The investor outreach culminated in a successful trade sale of the business to Perkin Elmer Inc.He served as Chief Financial Officer of Xtera Limited, a provider of subsea telecoms technology, from 2017 to 2018, and HOC Group, a construction company, from 2015 to 2016. From 2011 to 2015, he was in a Deputy Chief Financial Officer role at Asia Resource Minerals plc.Jayesh holds an M.B.A. from the London Business School and a degree in Accountancy from the University of East Anglia, and qualified with PricewaterhouseCoopers.

Jayesh Pankhania

Chief Financial Officer

Tom Barber

Position: Chief Scientific Officer
Categories: management

Tom has more than twenty years of experience working in the health care industry with extensive leadership experience in Pharma, LifeSciences and Healthcare IT. Most recently he served as Chief Scientific Officer at LifeOmic, where he was responsible for preclinical and clinical research. Prior to that, Dr Barber established Next Generation Sequencing (NGS) at Eli Lilly to identify preclinical and clinical models for personalised medicine in oncology, diabetes,  neuroscience, and cardiovascular disease. He then moved to Beckman Coulter, where he developed solutions for automated NGS sample preparation and assisted in the design and implementation of a strategic initiative aimed at developing a comprehensive sample-to-answer solution for research and clinical NGS.   

Tom Barber

Chief Scientific Officer

Sachin Saxena

Position: Chief Technology Officer
Categories: management

Sachin has over 15 years of experience in product development across multiple industries.

Prior to Congenica, Sachin was VP of Global Technology at Rocket Lawyer, where he was instrumental in growing the organisation and successfully launched new products into existing and new markets. He has led global teams and has implemented modern software practices enabling rapid delivery of great products that achieve customer value.

Sachin’s expertise lie in building high performance teams, technical leadership, championing innovation and managing rapid growth to meet the technological needs of today.

Sachin Saxena

Chief Technology Officer

Scientific Advisory Board

Richard Durbin, PhD

Position: Informatics Director
Categories: management, SAB

Richard is a Professor in the Department of Genetics at Cambridge University and Associate Faculty of the Wellcome Sanger Institute. A pioneer in genome sequencing and bioinformatics for over 25 years, he has developed sequence data analysis tools that are now standards in the field, including the alignment software bwa and the SAM/BAM format which underpin most clinical genomic data analysis. Richard has also made significant contributions to the Ensembl resource for vertebrate genome annotation, and the TreeFam and Pfam databases and led the international 1000 Genomes Project and the UK 10K Genome Project. Richard is a Fellow of the Royal Society and a Member of EMBO.

Richard Durbin, PhD

Informatics Director

Matthew Hurles, PHD

Position: Scientific Director
Categories: board, SAB

Matt is Head of Human Genetics and Senior Group Leader at the Wellcome Trust Sanger Institute. Matt is the scientific director of the Deciphering Developmental Disorders program and was a major contributor to the UK 10K projects. He has pioneered the analysis of whole exomes in clinically relevant disorders that previously failed diagnostic methods and has led an initiative to characterize structural variation in the human genome. Matt has been awarded the Balfour Lecture by the Genetics Society and the Crick Lecture prize for accomplishments in genetics and is a Fellow of the Royal Society.

Matthew Hurles, PHD

Scientific Director

Philip Beales, PhD

Position: Chief Medical Officer
Categories: management, SAB

Phil is a consultant clinical geneticist and Professor of Medical and Molecular Genetics at the UCL Institute of Child Health (ICH), an NIHR Senior Investigator, Honorary Consultant in Clinical Genetics at Great Ormond Street Hospital (GOSH) and the lead on Personalized Medicine for UCL. He is an internationally recognized expert in the genetics and pathogenesis of ciliopathies and pioneering use of next generation sequencing in mapping disease genes in this area.

Philip Beales, PhD

Chief Medical Officer

Nick Lench, PhD

Position: Co-Founder
Categories: SAB

Prior to founding Congenica, Nick was previously Director of Genetics Services at Great Ormond Street Hospital for Children, London, with responsibility for the strategic and operational management of a genetics service that provides DNA diagnostic testing and services to a population of approximately 4.5M people. Nick is an honorary Reader at the UCL Institute of Child Health and has over 25 years’ of academic, healthcare and commercial experience in medical genetics and genomics. He was awarded a personal chair in Medical Genetics at Cardiff University in 2005 and was a founding CEO of London Genetics Ltd and Programme Director at Oxagen Ltd.

Nick Lench, PhD

Co-Founder

Anne O’Donnell Luria, M.D., Ph.D.

Position: Associate Member; Associate director, Program in Medical and Population Genetics.
Categories: SAB

Anne O’Donnell-Luria is co-director of the Mendelian Genomics Research Center at the Broad Institute of MIT and Harvard, where she is an associate member as well as the associate director of the Program in Medical and Population Genetics. She is also an assistant professor of pediatrics at Harvard Medical School, a faculty member in the Division of Genetics and Genomics at Boston Children’s Hospital, and affiliated faculty in the Analytic and Translational Genetics Unit at Massachusetts General Hospital. Her research group at Boston Children’s Hospital and the Broad focuses on using large-scale genomic and transcriptomic approaches to increasing the rate of rare disease diagnosis through improving rare variant interpretation and empowering the discovery of novel disease genes. She is particularly interested in how we can leverage gnomAD, a massive reference population database, in these efforts including in estimating rare disease prevalence. She also studies incomplete penetrance of genetic conditions, or why only some people with a disease-causing genetic variant will develop symptoms.

Anne O’Donnell Luria, M.D., Ph.D.

Associate Member; Associate director, Program in Medical and Population Genetics.

Our quality assurance

Analyze and interpret all genomic data rapidly, reliably and with complete confidence